Who are zonisamide low dose group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Qudexy XR, carbamazepine oxcarbazepine, Topiramate monotherapy, Low dose zonisamide, Standard dose topiramate, Carbamazepine-Implant.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zonisamide-low-dose-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

zonisamide low dose group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

zonisamide low dose group (zonisamide low dose group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic agent. Area: Neurology.

marketed Anticonvulsant / Antiepileptic agent Sodium channels, calcium channels, carbonic anhydrase Neurology Small molecule Live · refreshed every 30 min

Target snapshot

zonisamide low dose group (zonisamide low dose group) — Eisai Korea Inc.. Zonisamide inhibits multiple ion channels and carbonic anhydrase to reduce neuronal excitability and seizure activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
zonisamide low dose group TARGET	zonisamide low dose group	Eisai Korea Inc.	marketed	Anticonvulsant / Antiepileptic agent	Sodium channels, calcium channels, carbonic anhydrase
Qudexy XR	Qudexy XR	Upsher-Smith Laboratories	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels
carbamazepine oxcarbazepine	carbamazepine oxcarbazepine	Odense University Hospital	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels
Topiramate monotherapy	Topiramate monotherapy	Johnson & Johnson Taiwan Ltd	marketed	Anticonvulsant / Antiepileptic agent	GABA-A receptor; voltage-gated sodium channels
Low dose zonisamide	Low dose zonisamide	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, T-type calcium channels, carbonic anhydrase
Standard dose topiramate	Standard dose topiramate	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase
Carbamazepine-Implant	Carbamazepine-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic agent class)

University of Sao Paulo · 2 drugs in this class
Mario Negri Institute for Pharmacological Research · 2 drugs in this class
Janssen Korea, Ltd., Korea · 1 drug in this class
Johnson & Johnson Taiwan Ltd · 1 drug in this class
Ministry of Health and Sports, Myanmar · 1 drug in this class
Odense University Hospital · 1 drug in this class
UCB BIOSCIENCES GmbH · 1 drug in this class
University Hospitals Cleveland Medical Center · 1 drug in this class
Eisai Korea Inc. · 1 drug in this class
Upsher-Smith Laboratories · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). zonisamide low dose group — Competitive Intelligence Brief. https://druglandscape.com/ci/zonisamide-low-dose-group. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing